About
Oncolines B.V., a subsidiairy of Symeres Netherlands B.V., is a precision medicine services company in oncology, immunology and cancer immunotherapy. Our Clients are clinical and preclinical biopharma companies and academic institutions that seek differentiation for their drugs and drug candidates. By cancer cell panel profiling, we identify predictive drug response biomarkers, new disease indications and synergistic drug combinations. We present results in a unique interactive reporting format to facilitate easier and faster interpretation of results. To investigate the mechanism of action of compounds, we perform gene and protein expression analysis, DNA and RNA sequencing. We generate, process, analyze, visualize, and interpret complex data. We present meaningful data and discuss them with our Clients. With our extensive reference compound database we identify differentiation and mechanism of action. We share our knowledge in cancer drug development. We help cancer researchers to move their projects to the clinic faster.
Oncolines B.V. was founded in 2021 as a spin-off company of Netherlands Translational Research Center B.V. (NTRC), a biotech company established in Oss (The Netherlands) in 2011 by former employees of Organon/MSD at the Pivot Park in Oss. Oncolines is named after its large cancer cell line panel (the Oncolines® panel) and its cell line proliferation assay and bioinformatics services. Oncolines was acquired by Symeres in January 2023. Symeres is a transatlantic CRO and CDMO with more than 600 employees in the Netherlands, Finland, Czech Republic and the United States.
Innovative human-based test models
2D & 3D in vitro cell culture models3D spheroids
Development stages and support fuctions
Early discovery / basic researchPre-clinical research and developmentClinical research and developmentData management and analytics
Innovative therapies:
Immune cell therapyPrecision medicine
High Tech Systems & Materials
Mask stabilizing, cleaning